Oncotelic Therapeutics Reports First-Quarter 2026 Results, Advances AI-Driven Drug Development and CNS Delivery Platform

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update, showcasing continued advancement across its oncology, AI-enabled drug development, and advanced drug delivery initiatives. The company highlighted progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform, underscoring its commitment to capital-efficient growth.

As of March 31, 2026, Oncotelic maintained the previously established fair value of approximately $388 million for its 45% ownership interest in GMP Biotechnology. This valuation reflects the company's strategic positioning in the biotechnology sector, leveraging partnerships to enhance its pipeline without significant capital outlay.

Oncotelic is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company's 45% interest in GMP Bio strengthens its position in oncology and rare disease therapeutics. The first-quarter results underscore Oncotelic's diversified biotechnology platform, which includes AI-driven drug development and advanced delivery systems like the nose-to-brain CNS platform.

For more details, the full press release is available at https://ibn.fm/DTVsF. Investors can find the latest news and updates on OTLC in the company's newsroom at https://ibn.fm/OTLC.